New drug shows promise for fatty liver in early trial
NCT ID NCT04006145
First seen Feb 05, 2026 · Last updated Jun 20, 2026 · Updated 22 times
Summary
This phase 2 trial tested the drug elobixibat in 47 adults with nonalcoholic fatty liver disease (NAFLD) or its more severe form, NASH. The study compared elobixibat to a placebo to see if it could lower LDL cholesterol and improve liver health over 16 weeks. The trial is now complete, and results will help determine if larger studies are warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAFLD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
American Research Corporation at the Texas Liver Institute
San Antonio, Texas, 78215, United States
-
Guardian Angel Research Center, Inc.
Tampa, Florida, 33614, United States
-
Hope Clinical Research
Canoga Park, California, 91303, United States
-
Inland Empire Clinical Trials, LLC
Rialto, California, 92377, United States
-
Integrity Clinical Research, LLC
Doral, Florida, 33166, United States
-
Mercy Medical Center
Baltimore, Maryland, 21202, United States
-
Nature Coast Clinical Research
Inverness, Florida, 34452, United States
-
Peak Gastroenterology Associates
Colorado Springs, Colorado, 80907, United States
-
University of Washington
Seattle, Washington, 98195, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elobixibat
What this could lead to
If successful, elobixibat could offer a new way to manage NAFLD/NASH by lowering cholesterol and potentially reducing liver fat.
What could go wrong
This is a small, early-phase trial with only 47 participants. The primary endpoint is a cholesterol marker, not a direct measure of liver disease improvement. Results may not confirm benefit or safety.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.